Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read More
    Services
    Clinical Research ServicesCommercial PositioningConsultingEarly PhaseFunctional Services ProvisionLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read More
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read More
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.
    Vaccines

    ICON has recently led the development of 17 vaccines resulting in FDA/EMA approvals. We are currently working on a number of COVID-19 vaccine trials.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read More
    Innovation
    ADDPLAN®FIRECRESTSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGE Medical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMS
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Connecting patients with the right trial in the right location.
    Patient Engagement Platform

    Connecting patients with the right trial in the right location.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read More
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Aggregated news on COVID-19 clinical trials.
    Coronavirus Observatory

    Aggregated news on COVID-19 clinical trials.

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read More
    News & Events
    Press ReleasesIn the NewsMediakitAwardsEventsWebinarsSocial Media
    Creating a world leader in healthcare intelligence and clinical research.
    ICON to acquire PRA Health Sciences

    Creating a world leader in healthcare intelligence and clinical research.

    13 April, 2021
    Webinar: The value of early phase medical communication planning

    13 April, 2021

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read More
    About ICON
    Company historyICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • EN | 日本語
  1. Home
  2. Insights
  3. Blog

Blog

  • 06 April 2021

    Navigating complexity of cell therapy manufacturing during the COVID-19 pandemic

    Over the past year, the COVID-19 pandemic significantly disrupted clinical research across the lifecycle including recruitment challenges, protocol amendments and delayed market entry.

  • 05 April 2021

    Navigating complexity in oncology cell and gene therapy clinical trials

    As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients

  • 01 April 2021

    Innovation in oncology drug development: A focus on patient benefits

    Improved diagnostic technologies, prevention methods and the advent of targeted therapeutic approaches have together contributed to lowering the mortality rate for the 10 most prevalent cancers

  • 29 March 2021

    Cell and gene therapy trials - delivering differently

    The success of cell and gene therapies (CGT) has transformed the delivery of clinical trial services, requiring the design of new workflows, processes and tools.

  • 24 March 2021

    Multidiagnostic approaches for patient selection biomarkers in immuno-oncology

    Advances in our understanding of cancer biology and the tumour microenvironment (TME), have led to the development of personalised drug and therapy designs to better prevent disease progression and relapse.

  • 22 March 2021

    Briefing: The UK NICE methods of health technology assessment

    In a statement on February 2021, the UK’s National Institute for Health and Care Excellence (NICE) launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.

  • 27 February 2021

    Sharing my rare disease story - Hayley Christensen

    ICON's Hayley Christensen shares her personal experience with Cystic Fibrosis.

  • 27 February 2021

    Sharing my rare disease story - Tamie Joeckel

    ICON's Tamie Joeckel shares her personal experience with Type 3 Hereditary Angioedema.

  • 26 February 2021

    Sharing my rare disease story - Amanda Huber

    ICON's Amanda Huber shares her personal experience with Alpha-1 Antitrypsin Deficiency (Alpha-1).

  • 25 February 2021

    Sharing my rare disease story - Julia Tonge

    ICON's Julia Tonge shares her personal experience with Amniotic Band Syndrome (ABS).

  • 09 February 2021

    mRNA vaccines from COVID-19 to HIV

    How one virus accelerated vaccine research, spurring innovation and hope for a cure in another

  • 05 February 2021

    Executing under pressure: Developing a strategy for high risk devices under IVDR

    Manufacturers who have not begun preparations will need to adopt a strategy to address gaps in meeting the new regulation.

  • 03 February 2021

    The Importance of partnering for bioanalytical studies

    Bioanalytical studies are an important aspect of biologic drug development that may necessitate partnering with bioanalysis experts.

  • 26 January 2021

    Clinical Evidence under IVDR - how much is enough?

    The new In Vitro Diagnostic Regulation (IVDR) aims to harmonise regulatory framework across the European Union (EU) to ensure the safety and performance of devices by placing greater responsibility on manufacturers to demonstrate that their products meet stringent requirements.

  • 18 January 2021

    Data capture: The benefits and evolution of eCOA

    As the demand for improving patient safety in clinical trials continues to rise, so will the use of technology as a way to better capture data and enhance clinical outcome assessments (COAs).

  • 12 January 2021

    Risk, vigilance, and remediation under IVDR

    The In Vitro Diagnostics Regulation (IVDR) — which goes into effect on May 26, 2022 — will have a lasting impact on the entire in vitro diagnostics (IVD) lifecycle, from development through clinical investigations and regulatory approval.

  • 08 January 2021

    Managing COVID disruptions within IVDR timelines

    The COVID-19 pandemic has greatly impacted the IVD industry, including travel and social distancing restrictions, creating hassles and stalling NB designation processes.

  • 06 January 2021

    Exploring the benefits of biotech partnerships

    The biotechnology sector is leading the way in developing innovative therapies that will address the unmet needs of many challenging diseases.

  • 04 January 2021

    Cancer research post-COVID-19

    The COVID-19 pandemic has been a catalyst for change in cancer research, forcing a shift towards remote monitoring, virtual arms and other uses of digital tools as global lockdowns reduce the ability of patients to go to clinics.

  • 09 December 2020

    Harnessing digital health to advance traumatic brain injury clinical trials

    Advances in wearable technology have provided an effective tool to monitor outcomes and facilitate the delivery of interventions in patients across indications, especially those in need of rehabilitation interventions.

In this section
In this section
  • Digital Disruption
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
    • Addressing cybersecurity for your medical device
    • Digital disruption in biopharma
    • Disruptive Innovation
    • mHealth & Wearables
      • Bring Your Own Device
      • Digital Endpoints
      • Transforming Medical Device Development with mHealth
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
  • Patient Centricity
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Decentralised and Hybrid clinical trials
    • Developing Nurse-Centric Medical Communications
    • Exploring the patient perspective from different angles
    • Mitigating the impact of COVID-19 on cardiovascular trials
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
  • Regulatory Intelligence
    • EU Regulations
      • IVDR Technical File Remediation
      • MDR and IVDR are Coming - Are you Prepared?
      • MDR / IVDR Brings Higher Costs and Bottlenecks
      • The IVDR journey
    • Regulatory Intelligence Newsletter
  • Therapeutics insights
    • Cardiovascular
    • Cell and Gene Therapies
      • Cell and Gene ebook
    • Central Nervous System
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Key Considerations in Chronic Pain Clinical Trials
    • Infectious Diseases
      • COVID-19 vaccine trials
      • HIV
    • Oncology
    • Rare and orphan diseases
      • Leveraging historical data for use in rare disease trials
      • Patient Centricity in Orphan Drug Development
  • Transforming Trials
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • CRO Partnership Strategies
    • Decentralised & hybrid clinical trials
    • Improving Pharma R&D Efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
  • Value Based Healthcare
    • US payers and PROs
    • Cardiovascular Medical Devices
    • COVID-19 navigating global market access
    • Global Outcomes Benchmarking
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • The Role of ICER as an HTA Organisation
  • Blog
  • Videos
  • Webinar Channel
  • Coronavirus Observatory
  • Decentralised & hybrid clinical trials

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What's happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content Preferences
ICON For
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press Releases
  • Mediakit
  • Events
  • Social Media Dashboard
  • Coronavirus Observatory
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2021 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media